Diana supports and leads on the commercialisation of MedTech, and HealthTech related technologies from Imperial’s Faculty of Engineering
Technology Sectors & Industries
Pharmaceuticals
Filter
A novel targeted drug delivery system
A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics
Dr Emily Allen-Benton
Emily is an IPC Executive within the Faculty of Medicine team focussed on intellectual property management, supporting Imperial academics with commercial engagement, fostering collaborative research and negotiating out-licenses. Emily manages an IP portfolio which...
Dr Amritha Nair
Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property;...
Novel treatment for Huntington’s Disease using zinc finger gene therapy
A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology.
A novel targeted drug delivery system
Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots.
Catch up: Innovations in engineering with AI and machine learning
This event highlighted some of the AI, machine learning and data-driven technologies from across Imperial that are being used for applications ranging from wireless video transfer to electric vehicle charging infrastructure, planning new offshore windfarms and optimising drug development and production.
Catch up: Affordable technologies for an ageing society
Imperial.Tech.Pitch: Affordable technologies for an ageing society centred on the premise that within 20 years, there will be 25% fewer taxpayers to pensioners in the UK than in 2020.
Catch up: Transition to zero pollution
Imperial.Tech.Pitch: Transition to zero pollution saw researchers and inventors from Imperial showcase their technologies and innovations that are helping companies and sectors to transition to a zero pollution future.
HKMT Inhibitors
Small molecule inhibitors with potential for use in the treatment of neurodegenerative diseases such as Huntington’s disease, viral conditions such as HIV, and cancers
Sign up for updates
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.